Bispecific Antibodies: A New Era in Therapeutic Innovation
Bispecific antibodies (bsAbs) are expanding the boundaries of modern therapeutics. By simultaneously engaging two different targets, these innovative molecules enable treatment strategies that can extend beyond the capabilities of traditional monoclonal antibodies.
Navigating the EMA Guideline on Equivalence of Topical Products: IVRT/IVPT Study Design
In April 2025, the long-awaited European Medicines Agency (EMA) Guideline on Quality and Equivalence of Locally Applied, Locally Acting Cutaneous Products came into effect.
Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus
Registration is now open for our free expert-led webinar on streamlined evidence strategies for biosimilar approval, with a special focus on analytics, PK design and immunogenicity.
Conscio Group at CPHI 2025 in Frankfurt – Meet Us in Hall 5.1, Stand F1
This October, the global pharmaceutical community will gather in Frankfurt for CPHI 2025. Conscio Group will be there too – visit us in the Contract Manufacturing Hall 5.1, Stand F1.
From Analytical Similarity to Clinical Data: Tailoring Evidence for Biosimilar Approval
Registration is now open for our free expert-led webinar on the evolving evidence requirements for biosimilar approval.
The Benefits of FTE Contracts for Pharmaceutical Companies
How can an FTE-based partnership with a CRO transform your pharmaceutical development?
Batch Release Testing and QP Certification: The Backbone of Pharmaceutical Quality Assurance
Are strict pharmaceutical regulations slowing your EU market entry? You’re not alone. Navigating the complex landscape of batch release testing can be challenging, particularly for pharmaceutical manufacturers outside the EU.
Conscio Group Appoints Gary Chambers as Executive Vice President of Strategy and Marketing
April 3, 2025 – Conscio Group, a leading scientific service provider for the pharmaceutical industry, announces the appointment of Gary Chambers as Executive Vice President (EVP) of Strategy and Marketing.
Expediting Biosimilar development: Streamlining the path from research to market
A free webinar on the future of biosimilar pathway to approval is now available for registration
Conscio Group and Kiel Labs Announce Strategic Partnership
Conscio Group, a European network of GMP/GLP/GCP/IEC-certified contract R&D service providers, and Kiel Laboratories, Inc., a leading U.S. pharmaceutical research and development company, today announced a strategic partnership to enhance drug development capabilities and market access for their respective clients.